YESINTEK DIN 02562103
Status: Marketed
Holder: BIOCON BIOLOGICS CANADA INC
Health Canada record
| Active ingredient(s) | USTEKINUMAB 90 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | L04AC05 USTEKINUMAB |
|---|
| Original market date | 24-Oct-2025 |
|---|
| Current status date | 21-May-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Biocon Biologics Canada Inc. — licence 3-002951, currently licensed, last inspection rating C (2026-06-23).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing USTEKINUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02537257 | FINLIUS | JANSSEN INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02537303 | FINLIUS | JANSSEN INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02537311 | FINLIUS I.V. | JANSSEN INC | Solution | USTEKINUMAB 5 MG | Marketed |
| 02564890 | IMULDOSA | ACCORD HEALTHCARE INC | Solution | USTEKINUMAB 45 MG | Approved |
| 02564904 | IMULDOSA | ACCORD HEALTHCARE INC | Solution | USTEKINUMAB 90 MG | Approved |
| 02564882 | IMULDOSA IV | ACCORD HEALTHCARE INC | Solution | USTEKINUMAB 5 MG | Approved |
| 02543036 | JAMTEKI | JAMP PHARMA CORPORATION | Solution | USTEKINUMAB 45 MG | Marketed |
| 02543044 | JAMTEKI | JAMP PHARMA CORPORATION | Solution | USTEKINUMAB 90 MG | Marketed |
| 02553120 | JAMTEKI I.V. | JAMP PHARMA CORPORATION | Solution | USTEKINUMAB 5 MG | Marketed |
| 02554291 | OTULFI | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 90 MG | Marketed |
| 02554283 | OTULFI | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 45 MG | Marketed |
| 02565420 | OTULFI | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 45 MG | Approved |
| 02554305 | OTULFI I.V. | FRESENIUS KABI CANADA LTD | Solution | USTEKINUMAB 5 MG | Marketed |
| 02563002 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 90 MG | Approved |
| 02550539 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 45 MG | Marketed |
| 02550547 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 90 MG | Marketed |
| 02562987 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 45 MG | Approved |
| 02562995 | PYZCHIVA | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 45 MG | Approved |
| 02550520 | PYZCHIVA I.V. | SAMSUNG BIOEPIS CO., LTD | Solution | USTEKINUMAB 5 MG | Marketed |
| 02320673 | STELARA | JANSSEN INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02320681 | STELARA | JANSSEN INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02459671 | STELARA I.V. | JANSSEN INC | Solution | USTEKINUMAB 5 MG | Marketed |
| 02566532 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 45 MG | Approved |
| 02550253 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 90 MG | Marketed |
| 02550245 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 45 MG | Marketed |
| 02566540 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 90 MG | Approved |
| 02558270 | STEQEYMA | CELLTRION INC. | Solution | USTEKINUMAB 45 MG | Approved |
| 02550261 | STEQEYMA IV | CELLTRION INC. | Solution | USTEKINUMAB 5 MG | Marketed |
| 02553317 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02544180 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02544199 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02553309 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 90 MG | Marketed |
| 02544202 | WEZLANA | AMGEN CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02544210 | WEZLANA I.V. | AMGEN CANADA INC | Solution | USTEKINUMAB 5 MG | Marketed |
| 02569833 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 45 MG | Approved |
| 02569841 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 90 MG | Approved |
| 02562081 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 45 MG | Marketed |
| 02566478 | YESINTEK | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 45 MG | Approved |
| 02562111 | YESINTEK I.V. | BIOCON BIOLOGICS CANADA INC | Solution | USTEKINUMAB 5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37620 | 2026-05-21 | New Drug Submission (NDS) | Administrative – Manufacturer name change |
| 37167 | 2025-10-17 | New Drug Submission (NDS) | |
Request a quote for YESINTEK
How to read a Canadian DIN record